These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10201659)

  • 1. Lipid-lowering medication and risk of cancer.
    Olsen JH; Johansen C; Sørensen HT; McLaughlin JK; Mellemkjaer L; Steffensen FH; Fraumeni JF
    J Clin Epidemiol; 1999 Feb; 52(2):167-9. PubMed ID: 10201659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer risk among statin users: a population-based cohort study.
    Friis S; Poulsen AH; Johnsen SP; McLaughlin JK; Fryzek JP; Dalton SO; Sørensen HT; Olsen JH
    Int J Cancer; 2005 Apr; 114(4):643-7. PubMed ID: 15578694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer risk in users of calcium channel blockers.
    Olsen JH; Sørensen HT; Friis S; McLaughlin JK; Steffensen FH; Nielsen GL; Andersen M; Fraumeni JF; Olsen J
    Hypertension; 1997 May; 29(5):1091-4. PubMed ID: 9149671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study.
    Gaist D; Rodríguez LA; Huerta C; Hallas J; Sindrup SH
    Epidemiology; 2001 Sep; 12(5):565-9. PubMed ID: 11505177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of lipid-lowering drugs during 1991-98 in Northern Jutland, Denmark.
    Riahi S; Fonager K; Toft E; Hvilsted-Rasmussen L; Bendsen J; Paaske Johnsen S; Sørensen HT
    Br J Clin Pharmacol; 2001 Sep; 52(3):307-11. PubMed ID: 11560563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?
    Gaist D; García Rodríguez LA; Huerta C; Hallas J; Sindrup SH
    Eur J Clin Pharmacol; 2001 Mar; 56(12):931-3. PubMed ID: 11317483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark.
    Friis S; Sørensen HT; Mellemkjaer L; McLaughlin JK; Nielsen GL; Blot WJ; Olsen JH
    Cancer; 2001 Nov; 92(9):2462-70. PubMed ID: 11745304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study.
    Blais L; Desgagné A; LeLorier J
    Arch Intern Med; 2000 Aug 14-28; 160(15):2363-8. PubMed ID: 10927735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
    García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
    Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering drugs and risk for cancer.
    Pedersen TR
    Curr Atheroscler Rep; 2009 Sep; 11(5):350-7. PubMed ID: 19664378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study.
    Pottegård A; Kristensen KB; Ernst MT; Johansen NB; Quartarolo P; Hallas J
    BMJ; 2018 Sep; 362():k3851. PubMed ID: 30209057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery.
    Lindenauer PK; Pekow P; Wang K; Gutierrez B; Benjamin EM
    JAMA; 2004 May; 291(17):2092-9. PubMed ID: 15126437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Common Cancers in Users of Antimuscarinic Medications for Overactive Bladder: A Danish Nationwide Cohort Study.
    Hallas J; Margulis AV; Pottegård A; Kristiansen NS; Atsma WJ; Appenteng K; de Vogel S; Kaye JA; Perez-Gutthann S; Arana A
    Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):612-619. PubMed ID: 29345103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
    Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
    BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study.
    Alpérovitch A; Kurth T; Bertrand M; Ancelin ML; Helmer C; Debette S; Tzourio C
    BMJ; 2015 May; 350():h2335. PubMed ID: 25989805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the utilisation of lipid-lowering drugs over a 6-year period (1993-1998) in a Danish population.
    Larsen J; Andersen M; Kragstrup J; Gram LF
    Eur J Clin Pharmacol; 2001 Jul; 57(4):343-8. PubMed ID: 11549214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinogenicity of lipid-lowering drugs.
    Newman TB; Hulley SB
    JAMA; 1996 Jan; 275(1):55-60. PubMed ID: 8531288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy.
    Larsen J; Vaccheri A; Andersen M; Montanaro N; Bergman U
    Br J Clin Pharmacol; 2000 May; 49(5):463-71. PubMed ID: 10792204
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.